Labs race to make pharmaceutical MDMA available to treat mental illness

The Globe & Mail

April 15, 2023

The Globe & Mail visited Filament's lab to interview our team regarding the production of MDMA and the Special Access Program.

Visit:

Labs race to make pharmaceutical MDMA available to treat mental illness

Read the full article

read more News

Blog

Voluntary Delisting: Summary & Explanation

April 28, 2025

Blog

Botanical Psilocybin & Alcohol Use Disorder: A Promising Treatment

April 23, 2025

Press Release

Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying PEX010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder

April 9, 2025

Recent News

Labs race to make pharmaceutical MDMA available to treat mental illness

read more News

Sign up for our newsletter